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Two commonly accepted features of soluble guanylyl
cyclase (sGC): its lack of "partners" and its exclusive-cyto-
plasmic localization were recently challenged. Several
proteins that bind directly to sGC have now been identi-
fied. The molecular chaperone Hsp70 is one of these sGC-
interacting proteins. Hsp70 modulates sGC activity, but
apparently requires other associated proteins or co-factors
for its sGC-activating effect. Other members of the molec-
ular chaperones family appear to interact with sGC as
well.
One of our aims is to determine the physiological rele-
vance of the sGC-Hsp70 association. So far, Hsp70 has
not been described as a classical activator, rather it is
known for assisting the folding of nascent polypeptides or
the association of multi-domains proteins, including
potentially sGC. Because Hsp70 and Hsp90 form a chap-
erone machinery that modulates various signaling path-
ways and because Hsp90 participates in the processing,
trafficking and maturation of nitric oxide synthase (NOS),
we postulate that the Hsp70-Hsp90 machinery could
modulate the NO-sGC pathway.
In particular, we wanted to determine whether the chap-
erone machinery could have a role in translocation of sGC
to the plasma membrane and in its maturation/degrada-
tion. To define the role of the chaperone machinery, we
blocked Hsp90 ATPase activity. We observed a decrease in
sGC activity in particulate and soluble fractions of cells
treated with Hsp90 inhibitors. This decrease in activity
was accompanied by a paralleled decrease of sGC levels in
the soluble fraction but not in the particulate fraction or
cell homogenates. Subcellular fractionation indicated that
the levels of sGC in cytosol and the plasma membrane
were greatly reduced in the presence of Hsp90 inhibitors.
These results not only confirmed that sGC can be associ-
ated with the plasma membrane but also suggest that
Hsp90 is involved in translocation of sGC to the mem-
brane and its maturation/degradation. We are currently
investigating the mechanisms of this Hsp90-dependent
modulation and the involvement of Hsp70 and other
chaperones.
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